SureTrader SureTrader
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
Followed By 18
Posts 3,170
Boards Moderated 0
Alias Born 06/09/10
160x600 placeholder
ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Pat... "Business Wire" - 12/5/2016 7:35:00 AM
ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer "Business Wire" - 12/2/2016 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/30/2016 4:06:56 PM
ARIAD Announces FDA Full Approval & Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy & Safety Data from Pha... "Business Wire" - 11/29/2016 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/18/2016 4:07:44 PM
ARIAD Announces Data Presentations at the World Conference on Lung Cancer "Business Wire" - 11/16/2016 5:04:00 PM
ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month "Business Wire" - 11/14/2016 7:35:00 AM
ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology "Business Wire" - 11/9/2016 7:35:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2016 5:34:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/7/2016 7:41:24 AM
ARIAD Reports Third Quarter 2016 Financial Results "Business Wire" - 11/7/2016 7:35:00 AM
ARIAD to Present at the Jefferies 2016 London Healthcare Conference "Business Wire" - 11/2/2016 7:35:00 AM
ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Results "Business Wire" - 11/1/2016 7:35:00 AM
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib "Business Wire" - 10/31/2016 7:35:00 AM
Goldberg Law PC Announces an Investigation of Ariad Pharmaceuticals Inc. & Advises Investors with Losses t... "Business Wire" - 10/28/2016 1:42:00 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Ariad Pharmaceuticals Inc. Investors "Business Wire" - 10/28/2016 12:33:00 PM
ARIAD Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research "Business Wire" - 10/26/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/25/2016 4:09:31 PM
U.S. Hot Stocks: Hot Stocks to Watch "Dow Jones News" - 10/21/2016 9:39:00 AM
ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers "Business Wire" - 10/20/2016 4:21:00 PM
ARIAD Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO M... "Business Wire" - 10/10/2016 7:35:00 AM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ariad Pharmaceuticals, Inc. (ARIA) "PR Newswire (US)" - 10/7/2016 12:21:00 PM
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ariad Pharmaceuticals, Inc. - ARIA "PR Newswire (US)" - 10/7/2016 11:08:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2016 4:20:17 PM
Biotechs and the Advancements in Cancer Oriented Clinical Trials "PR Newswire (US)" - 9/30/2016 9:00:00 AM
iandy   Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 79332 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.


It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist